Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (JAZZ), Acadia Healthcare (ACHC) and Genmab (GMAB)
Deutsche Bank Upgrades Acadia Healthcare(ACHC.US) to Buy Rating, Raises Target Price to $75
Deutsche Bank Upgrades Acadia Healthcare to Buy From Hold, Adjusts Price Target to $75 From $45
Cantor Fitzgerald Maintains Acadia Healthcare(ACHC.US) With Hold Rating, Cuts Target Price to $52
Acadia Healthcare Co Analyst Ratings
Cantor Fitzgerald Maintains Acadia Healthcare(ACHC.US) With Hold Rating, Cuts Target Price to $52
TD Cowen Maintains Acadia Healthcare(ACHC.US) With Buy Rating, Cuts Target Price to $70
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA), Acadia Healthcare (ACHC) and Bicara Therapeutics Inc. (BCAX)
Barclays Maintains Acadia Healthcare(ACHC.US) With Buy Rating, Maintains Target Price $43
Mizuho Securities Maintains Acadia Healthcare(ACHC.US) With Hold Rating, Announces Target Price $48
Acadia Healthcare Is Maintained at Overweight by Barclays
Barclays Maintains Acadia Healthcare(ACHC.US) With Buy Rating, Cuts Target Price to $43
Barclays Reaffirms Their Buy Rating on Acadia Healthcare (ACHC)
Deutsche Bank Maintains Acadia Healthcare(ACHC.US) With Hold Rating, Maintains Target Price $45
RBC Capital Maintains Acadia Healthcare(ACHC.US) With Buy Rating, Announces Target Price $64
Acadia Healthcare Is Maintained at Outperform by RBC Capital
Acadia Healthcare Co Analyst Ratings
RBC Cuts Price Target on Acadia Healthcare to $64 From $94, Keeps Outperform Rating
RBC Capital Reaffirms Their Buy Rating on Acadia Healthcare (ACHC)
TD Cowen Maintains Acadia Healthcare(ACHC.US) With Buy Rating, Cuts Target Price to $70